These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9533868)

  • 1. Analysis and application of an equilibrium model for in vitro bioassay systems with three components: receptor, hormone and hormone-binding-protein.
    Barnard R; Wolff RC
    J Theor Biol; 1998 Feb; 190(4):333-9. PubMed ID: 9533868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulus amplification, efficacy, and the operational model. Part II--ternary complex occupancy mechanisms.
    Trzeciakowski JP
    J Theor Biol; 1999 Jun; 198(3):347-74. PubMed ID: 10366491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of models for analysis of radioligand binding data.
    Abramson SN; McGonigle P; Molinoff PB
    Mol Pharmacol; 1987 Jan; 31(1):103-11. PubMed ID: 3027522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor mobility and catecholamine binding in membranes. A theoretical model.
    McGuire RF; Barber R
    J Supramol Struct; 1976; 4(2):259-69. PubMed ID: 177817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactant solutions and porous substrates: spreading and imbibition.
    Starov VM
    Adv Colloid Interface Sci; 2004 Nov; 111(1-2):3-27. PubMed ID: 15571660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ligand-receptor-G-protein ternary complex as a GTP-synthase. steady-state proton pumping and dose-response relationships for beta -adrenoceptors.
    Broadley KJ; Nederkoorn PH; Timmerman H; Timms D; Davies RH
    J Theor Biol; 2000 Jul; 205(2):297-320. PubMed ID: 10873440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reversible cross-linking of receptors by ligands: theory for the prediction of binding responses.
    Mark AE; Nichol LW; Jeffrey PD
    Biochem Int; 1990 Nov; 22(4):685-97. PubMed ID: 1964046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues.
    Sarkar CA; Lowenhaupt K; Wang PJ; Horan T; Lauffenburger DA
    Biotechnol Prog; 2003; 19(3):955-64. PubMed ID: 12790662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
    van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
    J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors.
    Gohlke H; Klebe G
    Angew Chem Int Ed Engl; 2002 Aug; 41(15):2644-76. PubMed ID: 12203463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational modeling of serum-binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds.
    Teeguarden JG; Barton HA
    Risk Anal; 2004 Jun; 24(3):751-70. PubMed ID: 15209943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of potency factors for asbestos-related lung cancer and mesothelioma.
    Berman DW; Crump KS
    Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural basis for biological signaling, regulation, and specificity in the growth hormone-prolactin system of hormones and receptors.
    Kossiakoff AA
    Adv Protein Chem; 2004; 68():147-69. PubMed ID: 15500861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor binding kinetics and cellular responses of six N-formyl peptide agonists in human neutrophils.
    Waller A; Sutton KL; Kinzer-Ursem TL; Absood A; Traynor JR; Linderman JJ; Omann GM
    Biochemistry; 2004 Jun; 43(25):8204-16. PubMed ID: 15209517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain.
    Kuznetsov VA; Puri RK
    Biophys J; 1999 Jul; 77(1):154-72. PubMed ID: 10388747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
    Gardner SN
    Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.